← Leaderboards
Krystle A. Kuhs
Vanderbilt University Medical Center
$3,664,442
Attributed
$3,879,973
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $967.5K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,879,973 · 4
By mechanism
R01$2,793,403 · 1
K07$593,828 · 1
R21$431,063 · 1
P30$61,679 · 1
Top collaborators
- Daniel Faden2 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Logan C Dumitrescu$7,599,480
- Stephanie Currin Demasi$185,720
Others in their field
Other Emerging Leaders on “Malignant Oropharynx Neoplasm”
- Fatemeh Momen Heravi · Columbia University Health Sciences$3,278,226
- Tim Lautenschlaeger · Indiana University Indianapolis$2,390,011
- J. Silvio Gutkind · University Of California, San Diego$2,102,598
- Sean T O'Leary · University Of Colorado Denver$2,078,331
- Amy Catherine Moreno · University Of Tx Md Anderson Can Ctr$2,064,685
- Tzu-Yin Lin · Theranostec, Inc.$1,925,106
Research focus
Malignant Oropharynx NeoplasmIncidenceHuman PapillomavirusHuman Papillomavirus 16CohortHead And Neck CancerBiological MarkersHigh RiskAntibodiesMiddle AgeDiagnosisSeropositiveCancer RiskHuman Papilloma Virus InfectionPositioning AttributeMalignant NeoplasmsOncoproteinsCollectionBiobankBaseScreening For CancerEarly DiagnosisBlood SpecimenBlood
Grant awards (16)
HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV$219,274
R01 · FY2025 · DE · contact PI
Cancer Prevention and Control Research Program$32,253
P30 · FY2025 · CA · contact PI
Cancer Prevention and Control Research Program$29,426
P30 · FY2024 · CA · contact PI
HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV$452,708
R01 · FY2023 · DE · contact PI
Circulating HPV DNA as a Prediagnostic Marker of Oropharyngeal Cancer$147,289
R21 · FY2023 · CA · contact PI
HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV$614,318
R01 · FY2022 · DE · contact PI
Circulating HPV DNA as a Prediagnostic Marker of Oropharyngeal Cancer$283,774
R21 · FY2022 · CA · contact PI
HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV$470,780
R01 · FY2021 · DE · contact PI
HPV16 E6 Antibody Detection as an Early Marker of Oropharyngeal Cancer Among Men Living with HIV$348,228
R01 · FY2021 · DE · contact PI
Human Papillomavirus-Specific Biomarkers for the Prediction of Oropharyngeal Cancer Recurrence$148,457
K07 · FY2021 · CA · contact PI
HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV$650,620
R01 · FY2020 · DE · contact PI
Human Papillomavirus-Specific Biomarkers for the Prediction of Oropharyngeal Cancer Recurrence$128,734
K07 · FY2020 · CA · contact PI
HPV16 E6 Antibody Detection as an Early Marker of Oropharyngeal Cancer Among Men Living with HIV$37,475
R01 · FY2020 · DE · contact PI
Human Papillomavirus-Specific Biomarkers for the Prediction of Oropharyngeal Cancer Recurrence$19,723
K07 · FY2020 · CA · contact PI
Human Papillomavirus-Specific Biomarkers for the Prediction of Oropharyngeal Cancer Recurrence$148,457
K07 · FY2019 · CA · contact PI
Human Papillomavirus-Specific Biomarkers for the Prediction of Oropharyngeal Cancer Recurrence$148,457
K07 · FY2018 · CA · contact PI